

1    **Title**

2    Neonatal LPS exposure results in ATP8A2 down-regulation in the prefrontal cortex  
3    and depressive-like behaviors in mice through increasing IFN- $\gamma$  level

4

5    **Authors**

6    Jiapeng Deng (ORCID: 0000-0002-0332-9296)<sup>a</sup> , Linyang Song (ORCID:  
7    0000-0002-2770-9568)<sup>b</sup>, Zhiqin Yang (ORCID: 0000-0002-3120-5944)<sup>c</sup>, Sixie Zheng  
8    (ORCID: 0000-0001-6603-7947)<sup>d</sup>, Zhuolin Du (ORCID: 0000-0003-0928-4081)<sup>d</sup>, Li  
9    Luo<sup>b,e</sup>, Jing Liu<sup>b</sup>, Xiaobao Jin<sup>e</sup>, Junhua Yang (ORCID: 0000-0001-8037-9644)<sup>b,e\*</sup>

10

11    **Affiliations**

12    <sup>a</sup> Class 1, Grade 2018, School of Clinical Medicine, Guangdong Pharmaceutical  
13    University, Guangzhou, Guangdong, People's Republic of China.

14    <sup>b</sup> Department of anatomy, School of Biosciences & Biopharmaceutics, Guangdong  
15    Pharmaceutical University, Guangzhou, Guangdong, People's Republic of China.

16    <sup>c</sup> Aviation health center, China southern airlines company limited, Guangzhou,  
17    Guangdong, People's Republic of China.

18    <sup>d</sup> Class 4, Grade 2018, School of Clinical Medicine, Guangdong Pharmaceutical  
19    University, Guangzhou, Guangdong, People's Republic of China.

20    <sup>e</sup> Guangdong Key Laboratory of Pharmaceutical Bioactive Substances, Guangdong  
21    Pharmaceutical University, Guangzhou, Guangdong, People's Republic of China.

22 **Corresponding author**

23 \*Correspondence should be addressed to Junhua Yang at the following address, phone,

24 and email address:

25 Address: Junhua Yang, Room 510#, Building of Basic Medical Sciences, School of

26 Biosciences & Biopharmaceutics, Guangdong Pharmaceutical University, No. 230,

27 East Waihuan Street, Higher Education Mega Center, Guangzhou City, Guangdong

28 Province, Postcode 510006, P. R. China.

29 Tel.: + 86 20 39352189.

30 E-mail: [jhyang2018@gdpu.edu.cn](mailto:jhyang2018@gdpu.edu.cn).

31

32

33

34

35

36

37

38

39

40

41

42 **Abstract**

43 Neonatal lipopolysaccharide (LPS) exposure can lead to depressive-like behaviors in  
44 mice through inducing pro-inflammatory cytokines including interferon(IFN)- $\gamma$ .  
45 ATP8A2 is a phospholipid transporter located on the cell membrane. Studies have  
46 shown that the decrease in ATP8A2 expression in the prefrontal cortex (PFC) is  
47 associated with depressive behavior. Moreover, it has been reported that IFN- $\gamma$  could  
48 reduce ATP8A2 expression in non-neuronal cells. These findings prompted us to  
49 hypothesize that neonatal LPS exposure might induce ATP8A2 down-regulation in  
50 PFC in mice by increasing the IFN- $\gamma$  level. Mice pups consisting approximately  
51 evenly of both sexes were intraperitoneally injected with 3 doses of LPS (50  $\mu$ g/kg  
52 body weight for each dose) on postnatal day (PND5), PND7 and PND9. Here, we first  
53 found that PFC ATP8A2 expression decreased significantly and transiently till ten  
54 days after neonatal LPS exposure with the lowest level at two days after it. Moreover,  
55 a negative correlation of PFC ATP8A2 expression was found with the PFC level of  
56 IFN- $\gamma$ , rather than the other LPS-induced pro-inflammatory cytokines. Using  
57 anti-IFN- $\gamma$  neutralizing mAb, IFN- $\gamma$  was identified as the key mediator of  
58 LPS-induced ATP8A2 down-regulation in PFC in mice. Besides, neutralizing IFN- $\gamma$   
59 partially but significantly rescued the depressive-like behaviors in adulthood induced  
60 by neonatal LPS exposure. In sum, the present study showed that neonatal LPS  
61 exposure induced ATP8A2 down-regulation in PFC and depressive-like behaviors in  
62 mice through increasing the IFN- $\gamma$  level.

63

64 **Keywords:** Neonatal period; Lipopolysaccharide/LPS; Interferon- $\gamma$ /IFN- $\gamma$ ; ATP8A2;  
65 prefrontal cortex/PFC; Depression

66

67 **Introduction**

68 ATP8A2, a member of the P4-ATPase family in mammals, is highly expressed in the  
69 brain, spinal cord, testis, and retina, which flipping phosphatidylserine and  
70 phosphatidylethanolamine across the cell membrane (Andersen et al., 2016). It plays  
71 an important role in maintaining the stability and normal function of the cell  
72 membrane (Coleman et al., 2009). Therefore, ATP8A2 in the brain is vital for normal  
73 neural development and function (Coleman and Molday, 2011; Xu et al., 2012), since  
74 these processes involve cell proliferation, migration, synapses pruning of neurons  
75 (Brandon and Sawa, 2011). ATP8A2 expressed in the brain has received extensive  
76 attention recently and researches have shown that reduced expression of ATP8A2  
77 leads to axonal mutation and neurodegenerative diseases (Choi et al., 2019; Zhu et al.,  
78 2012). There is also research reporting that ATP8A2 expression decreases in  
79 conditions of Alzheimer's disease and bacterial infection (Aaron et al., 2018; Ross et  
80 al., 2011). Moreover, depressive-like behavior has been reported to be associated with  
81 decreased ATP8A2 expression in the prefrontal cortex (PFC) (Chen et al., 2017).  
82 Although ATP8A2 has been widely studied, little is known about how ATP8A2  
83 expression is regulated.

84 Recently, IFN- $\gamma$  was shown to significantly reduce the expression of ATP8A2 in  
85 non-neuron cells (Shulzhenko et al., 2018). IFN- $\gamma$  produced in the periphery can

86 penetrate brain parenchyma across the immature blood-brain barrier and even increase  
87 the permeability of the mature blood-brain barrier (Hansen-Pupp et al., 2005; Wong et  
88 al., 2004). IFN- $\gamma$  may mediate the neonatal lipopolysaccharide (LPS)  
89 exposure-induced depressive-like behaviors in mice (Campos et al., 2014), which is  
90 associated with the function of PFC. Besides, IFN- $\gamma$  expression in PFC increased  
91 more than twice after LPS treatment (Laumet et al., 2018). Based on the background  
92 mentioned above, it was postulated that neonatal LPS exposure might induce ATP8A2  
93 down-regulation in PFC in mice by increasing the IFN- $\gamma$  level. There is yet no report  
94 addressing this issue.

95 To test this hypothesis, we challenged neonatal mice with LPS and observed a  
96 transiently decreased expression of ATP8A2 in PFC. Using a series of experiments,  
97 we further identified IFN- $\gamma$  as the key mediator of LPS-induced ATP8A2  
98 down-regulation in PFC in mice. These findings may reveal a potential mechanism by  
99 which early inflammation leads to impairment of the central nervous system  
100 development and function.

101

102 **2. Materials and methods**

103 *2.1. Animals designing*

104 Litters of newborn C57BL6/J mice (one-day-old) consisting approximately evenly  
105 of both sexes were ordered together with their mothers from Guangdong Medical  
106 Laboratory Animal Center (Guangzhou, China). They were housed in a specific

107 pathogen-free condition under 12 h light-12 h dark conditions with food and water  
108 available ad libitum.

109 In this study, a randomized block design was used to minimize the effects of  
110 systematic error according to publications by statisticians who stated that if the  
111 experimenters aim to focus exclusively on the differences between/among different  
112 treatment conditions, the effects due to variations between the different blocks should  
113 be eliminated by using a randomized block design ANOVA (Refer to  
114 [https://doi.org/10.1007/978-0-387-32833-1\\_344](https://doi.org/10.1007/978-0-387-32833-1_344);  
115 <http://www.r-tutor.com/elementary-statistics/analysis-variance/randomized-block-design>). In such design, there is only one primary factor under consideration in the  
116 experiment. Similar test subjects are grouped into blocks. Then, subjects within each  
117 block are randomly assigned to treatment conditions. Each block is tested against all  
118 treatment levels of the primary factor at random order. Thus, possible influence by  
119 other extraneous factors will be eliminated.

121 To be specific, a randomized block design was conducted for each of the  
122 experiments for investigating potential differences between or among treatment  
123 conditions. Each of the blocks consisted of two (for experiments reported in Fig.1 and  
124 Fig.2), three (for experiment reported in Fig.5) or five (for experiments reported in  
125 Fig.4 and Fig.6) same-sex pups from a same dam. The pups in each block were  
126 randomly assigned to different treatment conditions (only one pup in each block for  
127 receiving each kind of the different treatment conditions). The sex of n pups in  
128 different blocks were same or different, while the litter background of pups in

129 different blocks were certainly different. The detailed information indicating how  
130 many litters were used and how many pups from each litter were included in each  
131 group of each experiment in this study were shown in Supplementary table1 to table6  
132 (Supplementary Material). Pups subjected to behavioral tests were weaned on  
133 postnatal day (PND)21. Pups subjected to other tests were sacrificed on PND11. This  
134 study was approved by the Institutional Animal Ethics Committee of Guangdong  
135 Pharmaceutical University.

136 *2.2. LPS treatment*

137 Mice were intraperitoneally injected with 3 doses of LPS dissolved in 0.1 mol  
138 phosphate balanced solution (PBS) (Escherichia coli O111: B4; Sigma-Aldrich) (50  
139 µg/kg bodyweight for each dose;) on PND5, PND7 and PND9. The dosage and  
140 schedule for LPS injection were determined based on previous studies (Dinel et al.,  
141 2014; Doosti et al., 2013; Liang et al., 2019). The experiment was controlled by  
142 intraperitoneal injection of PBS. Littermates were toe-clipped for identification  
143 randomly assigned to each of the groups in each experiment as described in Results.

144 *2.3 Administration of anti-IFN-γ neutralizing mAb and an isotype IgG1*

145 For experiments conducted in this study as reported in Section 3.3 and Fig.4 to  
146 Fig.6, anti-IFN-γ neutralizing mAb and/or an isotype IgG1 (Invitrogen, Thermo  
147 Fisher Scientific, Waltham, MA, USA) were intraperitoneally injected daily to mice  
148 from PND5 to PND10. By a special experiment, the optimal dosage was first

149 determined as 0.6 mg/kg body weight of anti-IFN- $\gamma$  neutralizing mAb. The dosage of  
150 isotype IgG1 was determined as 0.6 mg/kg body weight accordingly.

151 *2.4 Western blot*

152 After being over-anesthetized with 10% chloral hydrate, the mice were decapitated  
153 and killed. The mouse PFC tissues were immediately taken on ice, and then  
154 homogenized in RIPA lysate containing protease inhibitors (Beyotime, Wuhan,  
155 China). After centrifuged at 13000g for 30 min at 4°C, the supernatant was taken. The  
156 BCA protein analysis method was used to determine the total protein content of the  
157 sample. After mixed with 5×SDS-PAGE loading buffer at the volume ratio of V  
158 (protein sample solution): V (5×SDS-PAGE Loading Buffer) = 4:1, the samples were  
159 boiled and denatured for 5 min, save for later use. The samples of each group were  
160 subjected to SDS polyacrylamide gel electrophoresis. The gel used here is a  
161 simplified hand-poured gradient gel, in which the ratio was 40% of the volume being  
162 6% acrylamide and 60% of the volume being 12% acrylamide (using an SDS-PAGE  
163 Gel Quick Preparation Kit, Beyotime, Shanghai, China). The procedure to make this  
164 gradient gel was according to a previous study (Miller et al., 2016) with modification  
165 with respect to the concentrations of acrylamide. When proteins were transferred to  
166 PVDF membranes, the membranes were cut according to the indication of the color  
167 marker (10-180 kDa, ThermoFisher, Shanghai, China). Two parts of each membrane,  
168 one located in the marker's range 70-180 kDa and the other in the range 25-55 kDa,  
169 containing the target proteins ATP8A2 (129 kDa) and the internal control proteins  
170  $\beta$ -actin (43 kDa) were subjected to the subsequent treatment. These membranes were

171 blocked with 5% skimmed milk powder at RT for 2 h. After this, these membranes  
172 were put into the corresponding primary antibody incubation solutions, one  
173 containing anti-ATP8A2 antibodies (1:500, Abcam, Cambridge, MA, USA) and the  
174 other containing anti- $\beta$ -actin antibodies (1:5000, Abcam, Cambridge, MA, USA) and  
175 incubated at 4°C overnight. After rinsing with TBST, these membranes were put into  
176 the corresponding secondary antibodies incubation solutions, one containing  
177 horseradish peroxidase (HRP)-conjugated goat anti-rabbit antibodies (1:5000,  
178 Bioworld, Atlanta, GA, USA) and the other containing HRP-conjugated goat  
179 anti-rabbit antibodies (1:5000, Bioworld, Atlanta, GA, USA) and incubated at RT for  
180 1 h. After rinsing with TBST, ECL luminescent solution is added on the membranes  
181 in a dark room for exposure and development. Chemiluminescent images were  
182 obtained with Carestream XBT X-ray Film (Rayco, Xiamen, Fujian, China), and  
183 subsequently scanned and quantified by densitometry using ImageJ software.

184 *2.5 Determination of cytokines levels*

185 Forty-eight h after the last LPS injection, the mice were anesthetized deeply with  
186 10% chloral hydrate before the blood was collected from the heart immediately. After  
187 blood collection, it was allowed to stand at room temperature for 1 h, and after  
188 centrifugation, the supernatant was taken and stored at -70°C for the experiment. Then  
189 the mice were transcranial perfused with 0.9% NaCl and PFC was collected  
190 immediately on ice. A mouse cytokine/chemokine magnetic bead panel  
191 (MCYTOMAG-70K-06; Millipore, Billerica, MA, USA) was employed to detect the  
192 levels of IFN- $\gamma$ , tumor necrosis factor (TNF)- $\alpha$ , interleukin(IL)-1 $\beta$ , IL-6 both in the

193 serum and PFC (Yang et al., 2016). Each of the serum samples was diluted at 1:2 in  
194 assay buffer. PFC tissue was prepared as homogenates before assayed. The total  
195 protein concentration of each sample was adjusted to 4.5 mg/ml using a BCA protein  
196 assay kit (Beyotime, Shanghai, China). Then, the prepared serum and PFC samples  
197 were used strictly according to the manufacturer's protocols for the multiplex assays.  
198 The data were collected on a Bio-Plex-200 system (Bio-Rad, Hercules, CA, USA) and  
199 analyzed using professional software (Bio-Plex Manager).

200 *2.6 Immunofluorescence and cell quantification*

201 Forty-eight h after the last LPS injection, the mice were over-anesthetized with 10%  
202 chloral hydrate and transcranial perfused with 0.9% NaCl followed by 4%  
203 paraformaldehyde (PFA). After removed, the brains were immediately post-fixed in 4%  
204 PFA overnight at 4 °C. Then, the brains were gradient dehydrated with 10%, 20%,  
205 and 30% sucrose for 24 h each at 4°C. Free-floating, serial coronal sections (40 µm)  
206 were collected on a Leica SM2000R freezing microtome (Leica Microsystems,  
207 Richmond Hill, Ontario, Canada) and stored at 4°C for immunostaining. Sections  
208 were washed in PBS three times and then blocked in PBS containing 1% bovine  
209 serum albumin (BSA) and 0.25% Triton X-100 (Sigma-Aldrich, St. Louis, MO, USA)  
210 for 1 h at 37°C. The slices were then incubated in the primary antibodies overnight at  
211 4°C. The primary antibodies, including rabbit anti-ATP8A2 (1:200; Abcam,  
212 Cambridge, MA, USA) and mouse anti-NeuN (1:1000; Abcam, Cambridge, MA,  
213 USA), were diluted in PBS containing 1% BSA and 0.25% Triton X-100. Afterward,  
214 the specimens were washed three times in PBS and then were incubated with

215 secondary antibodies, including Alexa Fluor 555-conjugated goat anti-rabbit and  
216 Alexa Fluor 488-conjugated donkey anti-mouse for 2 h at 37°C. Both secondary  
217 antibodies (Invitrogen, Thermo Fisher Scientific, Waltham, MA, USA) were diluted  
218 to 1:400.

219 A Stereo Investigator stereological system (MicroBrightField, Williston, USA) was  
220 used for quantitative analyses of the ATP8A2<sup>+</sup> cells in the unilateral PFC of each  
221 mouse. Coronal sections of the PFC were collected through the rostrocaudal axis  
222 spanning approximately from +3.20 mm to +2.10 mm relative to bregma (Xiong et al.,  
223 2017) to count the interested cells. Measurements were recorded from an equidistant  
224 series of six coronal sections. After the actual section thickness was measured,  
225 appropriate guard zones at the top and bottom of each section were defined to avoid  
226 oversampling. The 40× objective of a Nikon microscope was used for all stereological  
227 analyses. The numbers of ATP8A2<sup>+</sup>/NeuN<sup>+</sup> and NeuN<sup>+</sup> cells within the traced region  
228 (PFC) in each of the six selected sections were straightly quantified without using a  
229 grid or counting frames. A Zeiss LSM780 confocal laser-scanning microscope (Carl  
230 Zeiss AG, Oberkochen, Germany) was used to capture the representative confocal  
231 micrographs of the labeled cells.

232 For ATP8A2 in situ densitometric analysis, one 40-μm-thick coronal section at the  
233 middle of the PFC (+2.10 mm relative to bregma) was collected from each animal.  
234 Single labeling for ATP8A2 immunofluorescently was performed, rather than double  
235 labeling for ATP8A2/NeuN, to minimize the possible interference with ATP8A2  
236 positive immunofluorescence signal intensity during staining practice. A Zeiss

237 LSM780 confocal laser-scanning microscope (Carl Zeiss AG, Oberkochen, Germany)  
238 was used to capture the micrographs of the same field as the double-labeled  
239 micrographs shown in Fig.6D-F. The ATP8A2 signal was measured as a mean gray  
240 value using the software ImageJ and the data were shown in Fig.6 as a relative  
241 influence. The procedures were: 1) Image-Type-8bit; 2) Image-Adjust-Threshold; 3)  
242 Image-Adjust-Auto Threshold; 4) Analyze-Set Measurements; 5) Analyze-Measure.

243 *2.7. Forced swim test (FST)*

244 FST is a standard test used as a screen for measuring depressive-like behaviors in  
245 mice. The experiment was carried out on the PND90, the mice were brought to the  
246 laboratory one week in advance to let them adapt to the environmental room. In this  
247 experiment, mice were placed in a plastic cylinder (40 cm in-depth, 20 cm in diameter  
248 and filled with water at  $24\pm^{\circ}\text{C}$  with the water's height at 25 cm above from the  
249 bottom. Each mouse was put in the plastic cylinder in the same way and forced to  
250 swim for 6 min in the plastic cylinder. The first two minutes of mouse behavior was  
251 not recorded. The following 4 minutes were recorded by a video tracking system  
252 EthoVision (Noldus Information Technology B.V., Wageningen, Netherlands) for the  
253 analysis of the total time spent by each animal in staying on the water surface without  
254 any struggling or swimming during the test. At the end of the experiment, the hair of  
255 the mice was blown dry to prevent them from catching a cold.

256 *2.8 Tail-suspension test (TST)*

257 TST is also one of the most commonly used experiments to evaluate  
258 depressive-like behavior in rodent models. In the present study, TST was performed  
259 on the second day after the FST. During this test, each mouse was held below its tail  
260 to the edge of the clip and suspended 60 cm above from the floor. The performances  
261 of mice were recorded by a video tracking system EthoVision (Noldus Information  
262 Technology B.V., Wageningen, Netherlands) four minutes with a 2-min-gap left prior  
263 to the recording. The total time spent by each animal in not struggling during the test  
264 was analyzed. After all behavioral tests were done, animals were killed by  
265 over-anesthetized with 10% chloral hydrate.

266 *2.9 Statistical analyses*

267 The data were statistically analyzed using the SPSS 25.0 statistical software  
268 (Chicago, IL, USA). Pearson's correlation analysis was used for data shown in Fig.3.  
269 Data shown in Fig.1, Fig.2, Fig.4, Fig.5 and Fig.6 were statistically analyzed using a  
270 randomized block design ANOVA to account for the effects of treatment (such as LPS  
271 injection and/or anti-IFN- $\gamma$  neutralizing mAb injection) by modeling both litter factor  
272 and sex factor as a fixed effect described as “block effect” in section Results and the  
273 treatment factor as a random effect described as “treatment effect” in section Results.  
274 For data obtained from more than two treatment groups, the performance of  
275 randomized block design ANOVA were followed by Tukey's *post hoc* test. *P* values  
276 are displayed as follows: n.s. = not significant, \* *p* < 0.05, \*\* *p* < 0.01, \*\*\* *p* < 0.001.

278 **3. Results**

279 *3.1 Neonatal LPS exposure induced a transiently down-regulated expression of*  
280 *ATP8A2 in the PFC in mice*

281 To determine whether neonatal LPS exposure influence the expression of ATP8A2  
282 in the PFC in mice and how long this potential influence would last following LPS  
283 exposure, the first experiment was carried out. Mice in the LPS group were injected  
284 with LPS and those in the CON group with PBS of the same volume. Two groups of  
285 mice were sacrificed after 1 day, 2 days, 4 days, or 10 days after the last LPS injection.  
286 The left unilateral PFC tissue from every mouse was taken on ice to be homogenated  
287 immediately for Western blot analyses of ATP8A2 level. The right unilateral PFC  
288 tissue was taken on ice and stored at -70°C at once for ELISA analyses of  
289 LPS-induced pro-inflammatory cytokines if necessary.

290 As shown in Fig.1, the ATP8A2 levels significantly decreased at the former three  
291 test time points: 1 day (randomly block design ANOVA, block effect:  $F_{(5,5)} = 1.122, p$   
292  $= 0.451, n = 6$ ; treatment effect:  $F_{(1,5)} = 44.815, p = 0.001, n = 6$ ), 2 days (randomly  
293 block design ANOVA, block effect:  $F_{(5,5)} = 0.785, p = 0.601, n = 6$ ; treatment effect:  
294  $F_{(1,5)} = 77.139, p < 0.001, n = 6$ ) and 4 days (randomly block design ANOVA, block  
295 effect:  $F_{(5,5)} = 0.810, p = 0.588, n = 6$ ; treatment effect:  $F_{(1,5)} = 37.270, p = 0.002, n =$   
296  $6$ ) after the last LPS injection. However, such decrease was no longer detectable 10  
297 days after the last LPS injection (randomly block design ANOVA, block effect:  $F_{(5,5)}$   
298  $= 0.489, p = 0.775, n = 6$ ; treatment effect:  $F_{(1,5)} = 0.077, p = 0.792, n = 6$  ) (Fig.1). It

299 is worth noting that the largest extent of the decrease in PFC ATP8A2 expression was  
300 observed in the sample obtained 48 h after the last LPS injection (Fig.1). These  
301 findings verified the expected influence of neonatal LPS exposure on the PFC  
302 ATP8A2 expression in mice and revealed the time curve of PFC ATP8A2 expression  
303 following neonatal LPS exposure.

304 *3.2 PFC ATP8A2 level was only significantly correlated to IFN- $\gamma$  level among all four  
305 elevated pro-inflammatory cytokines both in serum and in the PFC*

306 Given the initial finding that PFC ATP8A2 expression was reduced to the largest  
307 extent 48 h after the last LPS injection (Fig.1), the prepared serum and PFC samples  
308 ( $n = 6$ ) obtained at the same time point in the last experiment were then subjected to  
309 ELISA analyses for the levels of LPS-induced pro-inflammatory cytokines, including  
310 IFN- $\gamma$ , IL-1 $\beta$ , IL-6 and TNF- $\alpha$ .

311 Moreover, another experiment was performed in which the animal was treated all  
312 the same way and the levels of PFC ATP8A2 as well as the levels pro-inflammatory  
313 cytokines both in the serum and PFC were detected specifically 48 h after the last LPS  
314 injection, using a larger sample size ( $n = 9$ ) so as both to provide a repetitive  
315 verification of the very novel finding of ATP8A2 in the brain and to make the total  
316 sample size up to  $n = 15$  (together with  $n = 6$ ) for this chosen test time point.

317 Pearson's correlation analysis between PFC ATP8A2 level and the level of each of  
318 the LPS-induced pro-inflammatory cytokines would get good confidence in the case  
319 of  $n = 15$ .

320 As shown in Fig.2A-B, the PFC ATP8A2 level decreased by more than 90% in LPS  
321 group (randomly block design ANOVA, block effect:  $F_{(8,8)} = 1.166, p = 0.417, n = 9$ ;  
322 treatment effect:  $F_{(1,8)} = 3.993, p < 0.001, n = 9$ ). All the detected cytokines, whether  
323 in serum (Fig.2C-F) or in PFC (Fig.2G-J), showed a dramatically increased  
324 expression (Serum IL-6: randomly block design ANOVA, block effect:  $F_{(8,8)} = 0.999$ ,  
325  $p = 0.500, n = 9$ ; treatment effect:  $F_{(1,8)} = 212.013, p < 0.001, n = 9$ . serum IFN- $\gamma$ :  
326 randomly block design ANOVA, block effect:  $F_{(8,8)} = 1.098, p = 0.449, n = 9$ ;  
327 treatment effect:  $F_{(1,8)} = 37.708, p < 0.001, n = 9$ ; serum IL-1 $\beta$ : randomly block design  
328 ANOVA, block effect:  $F_{(8,8)} = 1.053, p = 0.472, n = 9$ ; treatment effect:  $F_{(1,8)} = 93.958$ ,  
329  $p < 0.001, n = 9$ ; serum TNF- $\alpha$ : randomly block design ANOVA, block effect:  $F_{(8,8)} =$   
330  $0.952, p = 0.527, n = 9$ ; treatment effect:  $F_{(1,8)} = 181.681, p < 0.001, n = 9$ ; PFC IFN- $\gamma$ :  
331 randomly block design ANOVA, block effect:  $F_{(8,8)} = 1.145, p = 0.427, n = 9$ ;  
332 treatment effect:  $F_{(1,8)} = 134.25, p < 0.001, n = 9$ ; PFC IL-1 $\beta$ : randomly block design  
333 ANOVA, block effect:  $F_{(8,8)} = 1.668, p = 0.243, n = 9$ ; treatment effect:  $F_{(1,8)} = 62.695$ ,  
334  $p < 0.001, n = 9$ ; PFC IL-6: randomly block design ANOVA, block effect:  $F_{(8,8)} =$   
335  $0.990, p = 0.505, n = 9$ ; treatment effect:  $F_{(1,8)} = 184.902, p < 0.001, n = 9$ ; PFC  
336 TNF- $\alpha$ : randomly block design ANOVA, block effect:  $F_{(8,8)} = 0.995, p = 0.503, n = 9$ ;  
337 treatment effect:  $F_{(1,8)} = 105.007, p < 0.001, n = 9$ )  
338 Taken all the data from 48 h time point samples from LPS-treated mice together,  
339 Pearson's correlation analysis was performed between PFC ATP8A2 level and the  
340 level of each of the LPS-induced pro-inflammatory cytokines ( $n = 15$ ). There was a  
341 significant negative correlation between ATP8A2 expression in PFC and IFN- $\gamma$  level

342 both in serum ( $p < 0.01$ , Pearson's correlation analysis,  $n = 15$ ) (Fig.3 A) and in PFC  
343 ( $p < 0.001$ , Pearson's correlation analysis,  $n = 15$ ) (Fig.3E). No significant  
344 correlations were found between ATP8A2 level and all the other pro-inflammatory  
345 cytokines (all  $p$  values  $> 0.05$ ) (Fig.3 B-D, F-H). These results suggest that IFN- $\gamma$   
346 plays an important role in the PFC ATP8A2 down-regulation caused by neonatal LPS  
347 exposure.

348 *3.3 IFN- $\gamma$  mediated the PFC ATP8A2 down-regulation caused by neonatal LPS*  
349 *exposure*

350 To further explore the potential role of IFN- $\gamma$  in mediating the PFC ATP8A2  
351 down-regulation following neonatal LPS exposure, an IFN- $\gamma$ -blocking experiment  
352 was conducted using anti-IFN- $\gamma$  neutralizing mAb and an isotype IgG1. Before this  
353 IFN- $\gamma$ -blocking experiment, another experiment was carried out to determine the  
354 optimal dosage of anti-IFN- $\gamma$  neutralizing mAb. The dosage of 0.6 mg/kg body weight  
355 restored the IFN- $\gamma$  levels to normal physiological levels both in serum (randomly  
356 block design ANOVA, block effect:  $F_{(7,35)} = 0.449$ ,  $p = 0.864$ ,  $n = 8$ ; treatment effect:  
357  $F_{(5,35)} = 78.511$ ,  $p < 0.001$ ,  $n = 8$ ; *post hoc test*, LPS+anti-IFN- $\gamma$ (0.6) group vs. CON  
358 group:  $p = 1.000$ ) (Fig.4A) and in PFC (randomly block design ANOVA, block effect:  
359  $F_{(7,35)} = 0.718$ ,  $p = 0.657$ ,  $n = 8$ ; treatment effect:  $F_{(5,35)} = 35.571$ ,  $p < 0.001$ ,  $n = 8$ ;  
360 *post hoc test*, LPS+anti-IFN- $\gamma$ (0.6) group vs. CON group:  $p = 0.835$ ) (Fig.4B). Then,  
361 we proceeded to the IFN- $\gamma$ -blocking experiment and five groups of mice were set. To  
362 be specific, the CON group and LPS group were set as above. LPS+anti-IFN- $\gamma$ (0.6)  
363 group was set by injecting LPS combined with anti-IFN- $\gamma$  neutralizing mAb. The

364 LPS+IgG1 group was set by injecting LPS combined with an isotype IgG1. The last  
365 group was set by injecting mere anti-IFN- $\gamma$  neutralizing mAb (anti-IFN- $\gamma$ (0.6)).

366 Randomly block design ANOVA revealed significant differences in IFN- $\gamma$  levels  
367 among five groups (Fig.4C, serum IFN- $\gamma$  level: randomly block design ANOVA,  
368 block effect:  $F_{(7,28)} = 0.611, p = 0.742, n = 8$ ; treatment effect:  $F_{(4,28)} = 52.664, p <$   
369 0.001,  $n = 8$ ) (Fig.4D, PFC IFN- $\gamma$  level: randomly block design ANOVA, block effect:  
370  $F_{(7,28)} = 0.276, p = 0.958, n = 8$ ; treatment effect:  $F_{(4,28)} = 95.875, p < 0.001, n = 8$ ).

371 We first confirmed that administration of anti-IFN- $\gamma$  neutralizing mAb blocked the  
372 increase of IFN- $\gamma$  levels both in systemic blood (LPS+anti-IFN- $\gamma$ (0.6) group vs. CON  
373 group:  $p = 0.998$ ) (Fig.4C) and PFC (LPS+anti-IFN- $\gamma$ (0.6) group vs. CON group:  $p =$   
374 0.903) (Fig. 4D), while isotype IgG1 failed to block the LPS-induced IFN- $\gamma$  increase  
375 either in serum (LPS+IgG1 group vs. CON group:  $p < 0.001$  ; LPS+IgG1 group vs.  
376 LPS group:  $p = 0.976$ ) (Fig.4C) or in PFC (LPS+IgG1 group vs. CON group:  $p <$   
377 0.001; LPS+IgG1 group vs. LPS group:  $p = 0.563$ ) (Fig.4D). In the absence of LPS  
378 exposure, the anti-IFN- $\gamma$  neutralizing mAb significantly neutralized the physiological  
379 IFN- $\gamma$  both in blood (anti-IFN- $\gamma$ (0.6) group vs. CON group:  $p = 0.013$ ; LPS+IgG1  
380 group vs. LPS group:  $p = 1$ ) (Fig.4C) and in brain of mice (anti-IFN- $\gamma$ (0.6) vs. CON  
381 group:  $p < 0.001$ ; LPS+IgG1 group vs. LPS group:  $p = 1$ ) (Fig.4D).

382 Randomly block design ANOVA of Western blot data revealed significant  
383 differences in PFC ATP8A2 levels among five groups (Fig.4E, randomly block design  
384 ANOVA, block effect:  $F_{(7,28)} = 1.273, p = 0.099, n = 8$ ; treatment effect:  $F_{(4,28)} =$   
385 122.582,  $p < 0.001, n = 8$ ). We found that neutralization of IFN- $\gamma$  blocked the

386 LPS-induced ATP8A2 decrease in PFC (LPS+anti-IFN- $\gamma$ (0.6) group vs. CON group:  
387  $p = 1$ ) (Fig.4E-F), while the isotype IgG1 showed no significant blocking effect on the  
388 LPS-induced ATP8A2 decrease in PFC (LPS+IgG1 group vs. LPS group:  $p = 0.923$ ;  
389 LPS+IgG1 group vs. LPS+anti-IFN- $\gamma$ (0.6) group:  $p < 0.001$ ) (Fig.4E-F). Interestingly,  
390 in the absence of LPS exposure, mere anti-IFN- $\gamma$  neutralizing mAb administration led  
391 to no significant influence on the PFC ATP8A2 level (anti-IFN- $\gamma$ (0.6) group vs. CON  
392 group:  $p = 1$ ) (Fig.4E-F), although it neutralized the physiological IFN- $\gamma$  both in the  
393 blood (Fig.4C) and in the brain of mice (Fig.4D).

394 We next performed another experiment to observe the role of IFN- $\gamma$  using  
395 immunofluorescence detection, with a total of three groups set, CON group, LPS  
396 group, and LPS+anti-IFN- $\gamma$ (0.6) group. The groups by giving isotype IgG1 or mere  
397 anti-IFN- $\gamma$  neutralizing mAb were no longer set due to the confirmed results shown  
398 above. The results of randomly block design ANOVA of immunofluorescence  
399 detection of PFC ATP8A2 levels showed similar findings to Western blot.  
400 Neutralization of IFN- $\gamma$  blocked the LPS-induced ATP8A2 decrease in PFC, indicated  
401 by the mean fluorescence intensity (randomly block design ANOVA, block effect:  
402  $F_{(5,10)} = 0.472$ ,  $p = 0.789$ ,  $n = 6$ ; treatment effect:  $F_{(2,10)} = 47.016$ ,  $p < 0.001$ ,  $n = 6$ ;  
403 *post hoc test*, LPS+anti-IFN- $\gamma$ (0.6) group vs. CON group:  $p = 0.849$ ) (Fig.5K) and  
404 ATP8A2<sup>+</sup>/NeuN<sup>+</sup> cells (randomly block design ANOVA, block effect:  $F_{(5,10)} = 0.121$ ,  
405  $p = 0.985$ ,  $n = 6$ ; treatment effect:  $F_{(2,10)} = 47.016$ ,  $p < 0.001$ ,  $n = 6$ ; *post hoc test*,  
406 LPS+anti-IFN- $\gamma$ (0.6) group vs. CON group:  $p = 0.532$ ) (Fig.5L). Besides, there were  
407 no significant differences among three groups in the number of neurons (NeuN<sup>+</sup> cells)

408 in PFC (data are not shown) although nearly all patchy ATP8A2<sup>+</sup> signals were  
409 co-located with NeuN<sup>+</sup> signals (Fig.5G-I). The findings shown in this section  
410 identified IFN- $\gamma$  as the key mediator of the PFC ATP8A2 down-regulation caused by  
411 neonatal LPS exposure. Moreover, ATP8A2 alterations were not accompanied by a  
412 detectable change in the number of neurons (NeuN<sup>+</sup> cells) in PFC.

413 *3.4 IFN- $\gamma$  plays an important role in depressive-like behaviors in adulthood induced*  
414 *by neonatal LPS exposure*

415 Abnormality in PFC, especially during the critical development period, is an  
416 important pathophysiological basis of depression and it has been verified that  
417 *neonatal LPS exposure* could result in depression in adulthood (Dinel et al., 2014;  
418 Walker et al., 2013). Therefore, we investigated whether neutralization of IFN- $\gamma$   
419 affects the behavioral performances in the FST and TST of the LPS-treated mice. The  
420 floating immobility time was partially restored toward the levels of CON group both  
421 in FST task (randomly block design ANOVA, block effect:  $F_{(11,44)} = 0.825, p = 0.616,$   
422  $n = 12$ ; treatment effect:  $F_{(4,44)} = 36.675, p < 0.001, n = 12$ ; *post hoc test*,  
423 LPS+anti-IFN- $\gamma$ (0.6) group vs. CON group:  $p < 0.001$ ) (Fig.6A) and in TST task  
424 (randomly block design ANOVA, block effect:  $F_{(11,44)} = 0.949, p = 0.504, n = 12$ ;  
425 treatment effect:  $F_{(4,44)} = 35.619, p < 0.001, n = 12$ ; *post hoc test*, LPS+anti-IFN- $\gamma$ (0.6)  
426 group vs. CON group:  $p < 0.001$ ) (Fig.6B).

427 The isotype IgG1 failed to block the LPS-induced behavioral alterations either in  
428 FST (LPS+IgG1 group vs. CON group:  $p < 0.001$ ; LPS+IgG1 group vs. LPS group:  $p$

429 = 0.240) (Fig.6A) or in TST (LPS+IgG1 group vs. CON group:  $p < 0.001$  ; LPS+IgG1  
430 group vs. LPS group:  $p = 0.770$ ) (Fig.6B). In the absence of LPS exposure, the  
431 anti-IFN- $\gamma$  neutralizing mAb led to no significant behavioral alterations in FST  
432 (anti-IFN- $\gamma$ (0.6) group vs. CON group:  $p = 0.984$ ; LPS+IgG1 group vs. LPS group:  $p$   
433 = 0.770) (Fig.6A) or in TST (anti-IFN- $\gamma$ (0.6) vs. CON group:  $p = 0.617$ ) (Fig.6B).  
434 These results suggested an important role of IFN- $\gamma$  in depressive-like behaviors in  
435 adulthood induced by neonatal LPS exposure.

436 *3.5 No sex dimorphism in ATP8A2 levels despite a sex dimorphism in depressive-like*  
437 *behaviors in mice*

438 All the analyses described above were intended to exclusively detect the effects of  
439 different treatment conditions to test the hypothesis that neonatal LPS exposure might  
440 influence PFC ATP8A2 expression in mice involving an increased IFN- $\gamma$  level and  
441 therefore the sex factor was not under consideration as stated in section 2.1. However,  
442 previous studies showed that sex may affect immune activation (Cai et al., 2016). So,  
443 we also analyzed the data collected from the experiments in section 3.1 and 3.2 shown  
444 in Fig.2 as well as in the bars in Fig.1 indicated as day2 using another statistical  
445 method to observe whether there were significant differences in PFC ATP8A2  
446 expression and the levels of proinflammatory cytokines between two sexes either in  
447 the presence of LPS challenge or not. The results showed no significant differences in  
448 the levels of these molecules between male and female animals either in the presence  
449 of LPS challenge or not (all  $p$  values  $> 0.05$ , see details in Supplementary Fig.1 and  
450 its legend). Furthermore, data collected from behavioral tests and shown in section 3.4

451 (Fig.6) were also subjected to additional analysis for differences between two sexes.

452 The results showed no significant differences in the behavioral task performances

453 between male and female animals either in the presence of LPS challenge or not (all  $p$

454 values  $> 0.05$ , see details in Supplementary Fig.2 and its legend).

455

## 456 **Discussion**

457 Our research revealed that the neonatal LPS exposure induced ATP8A2

458 down-regulation in PFC and depressive-like behaviors in mice by increasing the

459 IFN- $\gamma$  level. This finding, based on a series of studies concerning the influence of LPS

460 on brain development and behavior (Bilbo and Schwarz, 2012; Doosti et al., 2013), is

461 the first to report the change of ATP8A2 in the PFC in this animal model and the

462 mechanism underlying how LPS affects PFC ATP8A2 expression. Moreover, this

463 study further extends our understanding of the mechanism underlying behavioral

464 effects of early immune activation.

465 Intraperitoneal LPS injection has been shown to cause a range of acute

466 physiological, pathological, and psychological disorders in rodents. Impairments both

467 in food intake and social exploratory behavior in rodents have been demonstrated in

468 rodents administered intraperitoneally with LPS (Haba et al., 2012; O'Reilly et al.,

469 1988). It has also been reported that LPS exposure can induce depressive and

470 anxiety-like behaviors (Depino, 2015; Doosti et al., 2013). Moreover, LPS may

471 reduce acutely the level of prefrontal cortical neurogenesis in adult rodents (Wang et

472 al., 2016). The data from the LPS-treated mice in the present study enriched these

473 widely reported neurobehavioral impairments.

474 LPS challenge may induce a large extent release of cytokines both in the periphery  
475 and brain, particularly pro-inflammatory cytokines, including IFN- $\gamma$ , IL-1 $\beta$ , IL-6, and  
476 TNF- $\alpha$  (Klimstra et al., 1999). These pro-inflammatory cytokines not only play an  
477 important role in immunity but also may affect brain function and mediate  
478 disease-like behaviors. For example, these pro-inflammatory factors have been shown  
479 to cause depressive-like behavior in mice (Gupta et al., 2016; Hashimoto, 2015;  
480 Kohler et al., 2014; Pokryszko-Dragan et al., 2012). The results of cytokines in our  
481 study showed clearly that their levels in the periphery and the brain were highly  
482 consistent. this fact may partially due to the immature blood-brain barrier or increased  
483 permeability of it during inflammation.

484 ATP8A2 is a protein located in the membrane, functioning to transport  
485 phosphatidylserine into the inner layer of membrane, and thus it is important to  
486 maintain the structural stability and normal function of the membrane (Andersen et al.,  
487 2016; Coleman et al., 2009). Since the distribution of ATP8A2 in the brain has been  
488 determined recently (Andersen et al., 2016), little has been known about the potential  
489 factors involved in the regulation of its expression. ATP8A2 expression  
490 down-regulation has been observed in certain pathological conditions including  
491 Alzheimer's disease and bacterial infection (Aaron et al., 2018; Ross et al., 2011).  
492 However, the study reported a mechanism underlying such regulation could not be  
493 seen so far. Decreased level of ATP8A2 in the PFC also occurs in the presence of  
494 stress and depressive situation (Chen et al., 2017), but the causal relationship between

495 ATP8A2 change and behavior change is unclear. The current study revealed that  
496 ATP8A2 expression in the PFC could be down-regulated by a high concentration of  
497 IFN- $\gamma$ , which is consistent with another study verifying that IFN- $\gamma$  down-regulated the  
498 expression of ATP8A2 in non-neuron cells (Shulzhenko et al., 2018). This finding  
499 deepens the understanding of how depression is induced during infections by  
500 LPS-producing gram-negative bacteria.

501 LPS exposure can induce neuroinflammation in various brain regions and result in  
502 functional abnormalities, such as hippocampal neuroinflammation and impaired  
503 learning and memory (Lee et al., 2008; Shaw et al., 2001). In this study, the animal  
504 model that simulates a depressive-like phenotype caused by early bacterial infection  
505 was used to investigate whether LPS caused alteration in ATP8A2 expression.  
506 Therefore, PFC was selected as the brain region to observe ATP8A2 expression that  
507 it's the area of the brain mostly focused on by studies about depressive-like behavior  
508 (Myers-Schulz and Koenigs, 2012). In future studies, we will investigate the  
509 expression of ATP8A2 in other pathological conditions and/or in other brain zones  
510 such as the hippocampus.

511 As well-known, LPS-induced inflammation is transient. Likewise, the first  
512 experiment in this study has shown the ATP8A2 levels decreased transiently and  
513 restored within 10 days after the end of LPS administration (Fig.1). Therefore, the  
514 animals were killed after finishing behavioral tasks by over-anesthetized without  
515 investigating their PFC ATP8A2 levels or peripheral/cerebral cytokines in adulthood.  
516 Understandably, a transient ATP8A2 decrease in PFC might mediate a delayed

517 depressive-like behavior phenotype due to the existing theory of early-life  
518 programming (Dinel et al., 2014; Karrow, 2006), saying that the brain is susceptible to  
519 external stimuli, such as immune activation, which modulates the course of normal  
520 brain development.

521 It has been reported that sex could affect the outcomes in behavior development by  
522 itself or combining neonatal immune activation (Cai et al., 2016), which is confirmed  
523 by the current study due to the observed between-sexes effects in FST and TST tasks  
524 performances (Supplementary Fig.2). However, the PFC ATP8A2 expression and  
525 cytokine levels both in blood and in PFC have not been significantly influenced by the  
526 sex factor tested at PND11 (Supplementary Fig.1). This may be because the sex factor  
527 exerts its effects mainly by gonadal hormones. These endocrine sex differences often  
528 come to be obvious from the beginning of puberty and these hormonal disparities  
529 contribute to the emerging sex differences in the brain (Cai et al., 2016). Further study  
530 is required to address whether the sex factor makes a difference in ATP8A2  
531 expression in the brain during puberty as well as adulthood.

532 In sum, our current research demonstrates that neonatal LPS exposure induces  
533 ATP8A2 down-regulation in PFC and depressive-like behaviors in mice through  
534 increasing the IFN- $\gamma$  level.

535

536 **Competing interests**

537 The authors declare that there are no conflicts of interest.

538

539 **Acknowledgments**

540 We thank Mr. Taoqi Tao (ORCID: 0000-0002-2770-9568, from GDPU), Mrs.  
541 Yinyin Xie (ORCID: 0000-0002-5858-3873, from GDPU) for their valuable  
542 discussions and help with this investigation. The work was supported by the starting  
543 fund for high-level talent introduction into Guangdong Pharmaceutical University  
544 (No.51355093), the National Natural Science Foundation of China (No.31600836),  
545 the Innovation and University Promotion Project of Guangdong Pharmaceutical  
546 University Through No. 2017KCXTD020, the National Natural Science Foundation  
547 of China (No.81901524), the Natural Science Foundation of Guangdong Province  
548 (No.2018A030313579).

549

550 **References**

551 Aaron, P.A., Jamklang, M., Uhrig, J.P., and Gelli, A. (2018). The blood-brain barrier  
552 internalises *Cryptococcus neoformans* via the EphA2-tyrosine kinase receptor. *Cell Microbiol*  
553 20.

554 Andersen, J.P., Vestergaard, A.L., Mikkelsen, S.A., Mogensen, L.S., Chalat, M., and Molday,  
555 R.S. (2016). P4-ATPases as Phospholipid Flippases-Structure, Function, and Enigmas. *Front*  
556 *Physiol* 7, 275.

557 Bilbo, S.D., and Schwarz, J.M. (2012). The immune system and developmental programming  
558 of brain and behavior. *Front Neuroendocrinol* 33, 267-286.

559 Brandon, N.J., and Sawa, A. (2011). Linking neurodevelopmental and synaptic theories of  
560 mental illness through DISC1. *Nat Rev Neurosci* 12, 707-722.

561 Cai, K.C., van Mil, S., Murray, E., Mallet, J.F., Matar, C., and Ismail, N. (2016). Age and sex  
562 differences in immune response following LPS treatment in mice. *Brain Behav Immun* *58*,  
563 327-337.

564 Campos, A.C., Vaz, G.N., Saito, V.M., and Teixeira, A.L. (2014). Further evidence for the role  
565 of interferon-gamma on anxiety- and depressive-like behaviors: involvement of hippocampal  
566 neurogenesis and NGF production. *Neurosci Lett* *578*, 100-105.

567 Chen, J., Wang, Z., Zhang, S., Ai, Q., Chu, S., and Chen, N.-h. (2017). Possible target-related  
568 proteins of stress-resistant rats suggested by label-free proteomic analysis. *RSC Advances* *7*,  
569 40957-40964.

570 Choi, H., Andersen, J.P., and Molday, R.S. (2019). Expression and functional characterization  
571 of missense mutations in ATP8A2 linked to severe neurological disorders. *Hum Mutat* *40*,  
572 2353-2364.

573 Coleman, J.A., Kwok, M.C., and Molday, R.S. (2009). Localization, purification, and functional  
574 reconstitution of the P4-ATPase Atp8a2, a phosphatidylserine flippase in photoreceptor disc  
575 membranes. *J Biol Chem* *284*, 32670-32679.

576 Coleman, J.A., and Molday, R.S. (2011). Critical role of the beta-subunit CDC50A in the stable  
577 expression, assembly, subcellular localization, and lipid transport activity of the P4-ATPase  
578 ATP8A2. *J Biol Chem* *286*, 17205-17216.

579 Depino, A.M. (2015). Early prenatal exposure to LPS results in anxiety- and  
580 depression-related behaviors in adulthood. *Neuroscience* *299*, 56-65.

581 Dinel, A.L., Joffre, C., Trifilieff, P., Aubert, A., Foury, A., Le Ruyet, P., and Laye, S. (2014).  
582 Inflammation early in life is a vulnerability factor for emotional behavior at adolescence and for

583 lipopolysaccharide-induced spatial memory and neurogenesis alteration at adulthood. *J*

584 *Neuroinflammation* *11*, 155.

585 Doosti, M.H., Bakhtiari, A., Zare, P., Amani, M., Majidi-Zolbanin, N., Babri, S., and Salari, A.A.

586 (2013). Impacts of early intervention with fluoxetine following early neonatal immune activation

587 on depression-like behaviors and body weight in mice. *Prog Neuropsychopharmacol Biol*

588 *Psychiatry* *43*, 55-65.

589 Gupta, R., Gupta, K., Tripathi, A.K., Bhatia, M.S., and Gupta, L.K. (2016). Effect of Mirtazapine

590 Treatment on Serum Levels of Brain-Derived Neurotrophic Factor and Tumor Necrosis

591 Factor-alpha in Patients of Major Depressive Disorder with Severe Depression. *Pharmacology*

592 *97*, 184-188.

593 Haba, R., Shintani, N., Onaka, Y., Wang, H., Takenaga, R., Hayata, A., Baba, A., and

594 Hashimoto, H. (2012). Lipopolysaccharide affects exploratory behaviors toward novel objects

595 by impairing cognition and/or motivation in mice: Possible role of activation of the central

596 amygdala. *Behav Brain Res* *228*, 423-431.

597 Hansen-Pupp, I., Harling, S., Berg, A.C., Cilio, C., Hellstrom-Westas, L., and Ley, D. (2005).

598 Circulating interferon-gamma and white matter brain damage in preterm infants. *Pediatr Res*

599 *58*, 946-952.

600 Hashimoto, K. (2015). Inflammatory biomarkers as differential predictors of antidepressant

601 response. *Int J Mol Sci* *16*, 7796-7801.

602 Karrow, N.A. (2006). Activation of the hypothalamic-pituitary-adrenal axis and autonomic

603 nervous system during inflammation and altered programming of the neuroendocrine-immune

604 axis during fetal and neonatal development: lessons learned from the model inflammagen,

605 lipopolysaccharide. *Brain Behav Immun* 20, 144-158.

606 Klimstra, W.B., Ryman, K.D., Bernard, K.A., Nguyen, K.B., Biron, C.A., and Johnston, R.E.

607 (1999). Infection of neonatal mice with sindbis virus results in a systemic inflammatory

608 response syndrome. *J Virol* 73, 10387-10398.

609 Kohler, O., Benros, M.E., Nordentoft, M., Farkouh, M.E., Iyengar, R.L., Mors, O., and Krogh, J.

610 (2014). Effect of anti-inflammatory treatment on depression, depressive symptoms, and

611 adverse effects: a systematic review and meta-analysis of randomized clinical trials. *JAMA*

612 *Psychiatry* 71, 1381-1391.

613 Laumet, G., Edralin, J.D., Chiang, A.C., Dantzer, R., Heijnen, C.J., and Kavelaars, A. (2018).

614 Resolution of inflammation-induced depression requires T lymphocytes and endogenous brain

615 interleukin-10 signaling. *Neuropsychopharmacology* 43, 2597-2605.

616 Lee, J.W., Lee, Y.K., Yuk, D.Y., Choi, D.Y., Ban, S.B., Oh, K.W., and Hong, J.T. (2008).

617 Neuro-inflammation induced by lipopolysaccharide causes cognitive impairment through

618 enhancement of beta-amyloid generation. *J Neuroinflammation* 5, 37.

619 Liang, M., Zhong, H., Rong, J., Li, Y., Zhu, C., Zhou, L., and Zhou, R. (2019). Postnatal

620 Lipopolysaccharide Exposure Impairs Adult Neurogenesis and Causes Depression-like

621 Behaviors Through Astrocytes Activation Triggering GABA<sub>A</sub> Receptor Downregulation.

622 *Neuroscience* 422, 21-31.

623 Miller, A.J., Roman, B., and Norstrom, E. (2016). A method for easily customizable gradient

624 gel electrophoresis. *Anal Biochem* 509, 12-14.

625 Myers-Schulz, B., and Koenigs, M. (2012). Functional anatomy of ventromedial prefrontal

626 cortex: implications for mood and anxiety disorders. *Mol Psychiatry* 17, 132-141.

627 O'Reilly, B., Vander, A.J., and Kluger, M.J. (1988). Effects of chronic infusion of  
628 lipopolysaccharide on food intake and body temperature of the rat. *Physiol Behav* **42**, 287-291.

629 Pokryszko-Dragan, A., Frydecka, I., Kosmaczewska, A., Ciszak, L., Bilinska, M., Gruszka, E.,  
630 Podemski, R., and Frydecka, D. (2012). Stimulated peripheral production of interferon-gamma  
631 is related to fatigue and depression in multiple sclerosis. *Clin Neurol Neurosurg* **114**,  
632 1153-1158.

633 Ross, A.E., Marchionni, L., Vuica-Ross, M., Cheadle, C., Fan, J., Berman, D.M., and Schaeffer,  
634 E.M. (2011). Gene expression pathways of high grade localized prostate cancer. *Prostate* **71**,  
635 1568-1577.

636 Shaw, K.N., Commins, S., and O'Mara, S.M. (2001). Lipopolysaccharide causes deficits in  
637 spatial learning in the watermaze but not in BDNF expression in the rat dentate gyrus. *Behav  
638 Brain Res* **124**, 47-54.

639 Shulzhenko, N., Dong, X., Vyshenska, D., Greer, R.L., Gurung, M., Vasquez-Perez, S.,  
640 Peremyslova, E., Sosnovtsev, S., Quezado, M., Yao, M., *et al.* (2018). CVID enteropathy is  
641 characterized by exceeding low mucosal IgA levels and interferon-driven inflammation  
642 possibly related to the presence of a pathobiont. *Clin Immunol* **197**, 139-153.

643 Walker, A.K., Budac, D.P., Bisulco, S., Lee, A.W., Smith, R.A., Beenders, B., Kelley, K.W., and  
644 Dantzer, R. (2013). NMDA receptor blockade by ketamine abrogates  
645 lipopolysaccharide-induced depressive-like behavior in C57BL/6J mice.  
646 *Neuropsychopharmacology* **38**, 1609-1616.

647 Wang, Z., Li, W., Chen, J., Shi, H., Zhao, M., You, H., Rao, C., Zhan, Y., Yang, Y., and Xie, P.  
648 (2016). Proteomic analysis reveals energy metabolic dysfunction and neurogenesis in the

649 prefrontal cortex of a lipopolysaccharide-induced mouse model of depression. *Mol Med Rep*  
650 13, 1813-1820.

651 Wong, D., Dorovini-Zis, K., and Vincent, S.R. (2004). Cytokines, nitric oxide, and cGMP  
652 modulate the permeability of an in vitro model of the human blood-brain barrier. *Exp Neurol*  
653 190, 446-455.

654 Xiong, B., Li, A., Lou, Y., Chen, S., Long, B., Peng, J., Yang, Z., Xu, T., Yang, X., Li, X., *et al.*  
655 (2017). Precise Cerebral Vascular Atlas in Stereotaxic Coordinates of Whole Mouse Brain.  
656 *Front Neuroanat* 11, 128.

657 Xu, Q., Yang, G.Y., Liu, N., Xu, P., Chen, Y.L., Zhou, Z., Luo, Z.G., and Ding, X. (2012).  
658 P4-ATPase ATP8A2 acts in synergy with CDC50A to enhance neurite outgrowth. *FEBS Lett*  
659 586, 1803-1812.

660 Yang, J., Qi, F., Gu, H., Zou, J., Yang, Y., Yuan, Q., and Yao, Z. (2016). Neonatal BCG  
661 vaccination of mice improves neurogenesis and behavior in early life. *Brain Res Bull* 120,  
662 25-33.

663 Zhu, X., Libby, R.T., de Vries, W.N., Smith, R.S., Wright, D.L., Bronson, R.T., Seburn, K.L.,  
664 and John, S.W. (2012). Mutations in a P-type ATPase gene cause axonal degeneration. *PLoS*  
665 *Genet* 8, e1002853.

666

667

668

669

670

671 **Legends**

672 **Fig.1. Neonatal LPS exposure induced a transiently down-regulated expression**

673 **of ATP8A2 in the PFC in mice. (A)** Representative results for the Western blot

674 analysis of ATP8A2. **(B)** The relative quantification of ATP8A2 in each group of mice

675 was normalized using the level of  $\beta$ -actin. Data are expressed as means  $\pm$  SEM.

676 Randomly block design ANOVA;  $n = 6$ /group; \*  $p < 0.05$ ; \*\*\*  $p < 0.001$ .

677 **Fig.2. Neonatal LPS exposure induced a down-regulated expression of ATP8A2**

678 **accompanied by inflammation both in periphery and in PFC in mice.**

679 **(A)** Representative results for the Western blot analysis of ATP8A2. **(B)** The relative

680 quantification of ATP8A2 in each group of mice was normalized using the level of

681  $\beta$ -actin. **(C-J)** The bars represent the average levels of IFN- $\gamma$ , IL-1 $\beta$ , IL-6, TNF- $\alpha$  in

682 the serum and IFN- $\gamma$ , IL-1 $\beta$ , IL-6, TNF- $\alpha$  in the PFC. Data are expressed as means  $\pm$

683 SEM. Randomly block design ANOVA;  $n = 9$ /group; \*  $p < 0.05$ ; \*\*  $p < 0.01$ ; \*\*\*  $p <$

684 0.001.

685 **Fig.3. The correlation of PFC ATP8A2 level with the serum and PFC levels of**

686 **pro-inflammatory cytokines in mice. (A)** The positive negative correlation of the

687 PFC IFN- $\gamma$  level with the ATP8A2 expression level in LPS-treated mice. **(B-D)**

688 Correlation analyses between the PFC IL-1 $\beta$ , IL-6 and TNF- $\alpha$  levels and the level of

689 ATP8A2 LPS-treated mice. **(E)** The positive negative correlation of the serum IFN- $\gamma$

690 level with the ATP8A2 expression level in LPS-treated mice. **(F-H)** Correlation

691 analyses between the serum IL-1 $\beta$ , IL-6 and TNF- $\alpha$  levels and the level of ATP8A2

692 LPS-treated mice.  $n = 15$  per analysis ; Pearson's correlation analysis.



693 **Fig.4. Western blot analyses showed that IFN- $\gamma$  mediated the PFC ATP8A2**  
694 **down-regulation caused by neonatal LPS exposure.**











695 **(A-B)** The mean levels of IFN- $\gamma$  in the serum and PFC were shown from the  
696 experiment carried out to determine the optimal dosage of anti-IFN- $\gamma$  neutralizing  
697 mAb. **(C-D)** The mean levels of IFN- $\gamma$  in the serum and PFC were shown from the  
698 IFN- $\gamma$ -blocking experiment. **(E)** The relative quantification of ATP8A2 in each group  
699 of mice was normalized using the level of  $\beta$ -actin. **(F)** Representative results for the  
700 Western blot analysis of ATP8A2. Data are expressed as means  $\pm$  SEM. Randomly  
701 block design ANOVA followed by Tukey's *post hoc* test;  $n = 8$ /group; \*\* $p < 0.01$ ;  
702 \*\*\*  $p < 0.001$ ; n.s., no significant. anti-IFN- $\gamma$ (0.6), the anti-IFN- $\gamma$  dosage of 0.6  
703 mg/kg body weight.









704 **Fig.5. Immunofluorescence analyses showed that IFN- $\gamma$  mediated the PFC**  
705 **ATP8A2 down-regulation caused by neonatal LPS exposure. (A-C)** Representative  
706 immunofluorescence staining results in the PFC for ATP8A2(red)/NeuN(green)  
707 co-labeling in CON group (A), LPS group (B) and LPS+anti-IFN- $\gamma$ (0.6) group (C).  
708 **(E-F)** Exhibition of the single red channel that shows ATP8A2 signal of the same  
709 micrographs shown in (A), (B), (C), respectively. **(G-I)** Representative high  
710 magnification photos show the immunofluorescence staining results in the PFC for  
711 ATP8A2/NeuN co-labeling. Thick arrows indicate ATP8A2/NeuN co-labeling cells.  
712 Thin arrows indicate NeuN single labeling cells. **(J)** The larger scope shows the

713 location in PFC where the photos shown in (G-I) come from. **(K)** Bars represent mean  
714 fluorescence intensity of the signal of immunofluorescence staining for ATP8A2 in  
715 each group. **(I)** Bars represent mean numbers of ATP8A2/NeuN co-labeling cells in  
716 unilateral PFC in each group. Data are expressed as means  $\pm$  SEM. Randomly block  
717 design ANOVA followed by Tukey's *post hoc* test;  $n = 6$ /group; \*\*\*  $p < 0.001$ ;  
718 anti-IFN- $\gamma$ (0.6), the anti-IFN- $\gamma$  dosage of 0.6 mg/kg body weight. Scale bar in (A-F),  
719 300  $\mu$ m; in (G-I), 10  $\mu$ m; in (J), 200  $\mu$ m.






720 **Fig.6. IFN- $\gamma$  plays an important role in depressive-like behaviors in adulthood**  
721 **induced by neonatal LPS exposure.** **(A)** Bars represent the mean immobility time of  
722 mice in FST of each group. **(I)** Bars represent the mean immobility time of TST in  
723 each group. The data represent the mean  $\pm$  SEM; randomly block design ANOVA  
724 followed by Tukey's *post hoc* test;  $n = 12$ /group; \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$ ;  
725 anti-IFN- $\gamma$ (0.6), the anti-IFN- $\gamma$  dosage of 0.6 mg/kg body weight.

**A****B**

**A****B****C****D****E****F****G****H****I****J**

**A****B****C****D****E****F****G****H**

ATP8A2 relative level



CON  
LPS  
LPS+anti-IFN- $\gamma$  (2.4)  
LPS+anti-IFN- $\gamma$  (1.2)  
LPS+anti-IFN- $\gamma$  (0.6)  
LPS+anti-IFN- $\gamma$  (0.3)  
LPS+IgG1  
anti-IFN- $\gamma$  (0.6)



